Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).

Giuseppe Procopio,Alessia Mennitto,Massimo Di Maio,Emma Zattarin,Marco Maruzzo,Ugo De Giorgi,Daniele Santini,Sebastiano Buti,Chiara Casadei,Mariella Sorarů,Giuseppe Di Lorenzo,Carlo Messina,Claudia Mucciarini,Giandomenico Roviello,Consuelo Buttigliero,Marco Stellato,Pierangela Sepe,Sandro Pignata,Filippo de Braud,Elena Verzoni

Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).

2021

320Background: The multikinase inhibitor cabozantinib (Cabo) is an effective treatment option for metastatic renal cell carcinoma (mRCC). However, data on the optimal sequencing of Cabo and other a...

Keywords:

Oncology
effective treatment
Renal cell carcinoma
multikinase inhibitor
Cabozantinib
Medicine
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations